| Autor: |
Stefaan W. Van Gool, Jennifer Makalowski, Michael Bitar, Peter Van de Vliet, Volker Schirrmacher, Wilfried Stuecker |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Genes and immunity. 23(8) |
| ISSN: |
1476-5470 |
| Popis: |
The prognosis of IDH1 wild-type MGMT promoter-unmethylated GBM patients remains poor. Addition of Temozolomide (TMZ) to first-line local treatment shifted the median overall survival (OS) from 11.8 to 12.6 months. We retrospectively analyzed the value of individualized multimodal immunotherapy (IMI) to improve OS in these patients. All adults meeting the criteria and treated 06/2015–06/2021 were selected. Thirty-two patients (12f, 20m) had a median age of 47 y (range 18–69) and a KPI of 70 (50–100). Extent of resection was complete (11), p = 0.0001) different from group-1. The data suggest that addition of IMI after local therapy on its own has no relevant effect on OS in these GBM patients, similar to maintenance TMZ. However, the combination of both TMZ + IMI significantly improved OS. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink